Our Pipeline
Target class
Indication
Molecule
Program
Discovery
Preclinical
Phase i/ii
Phase iii
Cytokine
Solid Tumors
IL-12
Undisclosed
Undisclosed
Undisclosed
ANK-101
ANK-102
ANK-103
ANK-104
Antibody
Solid Tumors
Undisclosed
Undisclosed
ANK-201
ANK-202
Lead Product Candidate: Tolododekin alfa (ANK-101)
No IL-12 based therapies have yet been approved
Key Challenges:
- Drugs have yielded minimal efficacy at acceptable doses
- High toxicity concerns limit clinical trial success
Tolododekin alfa (ANK-101) is an IL-12 Anchored Drug Conjugate
- Drug designed to extend IL-12 antitumor activity in tumors​
- Optimized phosphorylation on alum-binding peptdite (ABP) leads to stable anchoring of IL-12
- Drug shows potent therapeutic activity after a single dose as a monotherapy and in combination with other agents in multiple murine tumor models
- Has favorable safety profile (no dose-limiting toxicities) in mice, dogs, and non-human primates